The MInimizing RIsk of CLotting Events Trial

The registry criteria, word for word

What the trial wants to find out

The goal of this clinical trial is to evaluate whether the implementation of a real-time prognostic model can effectively identify and prevent blood clots among hospitalized patients. The main questions it aims to answer is:

The 2 groups in the trial

• Control: Standard of CareNo study treatment, for comparison

  For patients randomized to the control arm, the clinical care team will administer standard of care at VUH and monitor their patients' risk for HA-VTE in accordance with existing protocols and procedures. Standard of care includes assessing patient risk for VTE and initiating prophylaxis if necessary, usually using an order set. If the clinical care team determines that the patient has elevated risk and no contraindications, they will initiate and order prophylaxis using their service line-specific order set and continue to monitor the patient for any complications. Providers caring for patients in the control arm will not be shown the HA-VTE risk score anywhere in the EHR, which is the status quo.

• Intervention: Standard of Care PLUS risk assessment modelExisting treatment, for comparison

  Standard of care plus risk assessment model: the prognostic model will automatically calculate a patient's risk score daily based on 17 risk factors. For patients randomized to the intervention, the clinical care team will see the patient's predicted risk score during their standard risk assessment process, which will be embedded in their EHR workflow. The clinical care team will have access to review the patient's risk score in conjunction with their clinical judgment to guide decision-making surrounding risk assessment and initiation of prophylaxis (if applicable).

  Treatment: VTE Risk Assessment CDS Tool